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Background: The role of “Jun-Chen-Zuo-Shi” (also known as “sovereign-minister-assistant-courier”) component herbs
of Chinese medicine is not fully understood. This study aims to test the “Jun-Chen-Zuo-Shi” rule with the QiShenYiQi
formula (QSYQ) on treating acute myocardial ischemia (AMI) by a network pharmacology approach.
Methods: An Acute Myocardial Ischemia (AMI) specific Organism Disturbed Network (AMI-ODN), was constructed by
integrating data of disease-associated genes, protein-protein interaction and microarray experiments. A network-based
index, Network Recovery Index for Organism Disturbed Network (NRI-ODN), was developed to measure the therapeutic
efficacy of QSYQ and its ingredients, i.e., the ability to recover disturbed AMI network model back to normal state.
Results: The whole formula of QSYQ got a NRI-ODN score of 864.48, which outperformed all individual herbs.
Additionally, the primary component herbs, Radix Astragalus membranaceus and Radix Salvia miltiorrrhiza
showed NRI-DON score of 680.27 and 734.31 respectively, which meant a better performance to recover disturbed
AMI network than the supplementary component herbs, Panax notoginseng and Dalbergia sissoo did (545.76 and
584.88, respectively).
Conclusion: AMI-ODN model and NRI-ODN identified the possible roles of “Jun-Chen-Zuo-Shi” component herbs
of QSYQ in treating AMI at molecular network and pathway level.Introduction
Abnormalities in molecular pathways and their interac-
tions have been observed in human diseases [1,2]. Mul-
tiple components simultaneously act on multi-targets,
such as in the antiretroviral triple cocktail therapy for
acquired immunodeficiency syndrome [3], has been con-
sidered in drug development. Chinese medicine (CM),
featured as ‘multiple ingredients and multiple targets’
[4], is based on “Jun-Chen-Zuo-Shi” (also known as “sov-
ereign-minister-assistant-courier”) rule, which explains
the complex actions of a CM such as Indigo naturalis to
treat promyelocytic leukemia [5]. However, the “Jun-
Chen-Zuo-Shi” rule has not been fully understood and
demonstrated in pharmacological science.* Correspondence: fanxh@zju.edu.cn
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lationships between diseases and CM [6-10]. In a previ-
ous study, we developed network recovery index (NRI)
to systemically evaluate drug efficacy by a microarray
data annotated biological network [11]. NRI is a quanti-
tative index to measure the ability of a drug to recover
perturbed biological network. The NRI measured the
synergistic drug efficacy of SHENMAI injection consist-
ing of Red ginseng and Radix Ophiopogonis in treating
acute myocardial ischemia (AMI) [11].
QiShenYiQi (QSYQ) was a CM prescription for treating
ischemic heart disease, while QI-SHEN-YI-QI Dropping
Pill was approved by the China Food and Drug Adminis-
tration (CFDA) in 2003 [12]. QSYQ comprises Radix
Astragalus membranaceus (referred later as Astragalus),
Radix Salvia miltiorrrhiza (referred later as Salvia),
Panax notoginseng (referred later as Notoginseng)
and Dalbergia odorifera T. Chen (referred later as. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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http://www.cmjournal.org/content/9/1/24Dalbergia). These herbs constitute the QSYQ formula
based upon the principle rule of “Jun-Chen-Zuo-Shi”,
where Astragalus serves as the sovereign, Salvia
serves as the minister, Notoginseng serves as the as-
sistant, and Dalbergia serves as the courier [12,13].
QSYQ exhibited a protective effect comparable to as-
pirin in preventing myocardial infarction as tested in a
double-blind randomized controlled trial [14], QSYQ also
significantly reduced infarct size of heart with LAD
ligation and increased the density of vessel in ischemic
heart in rats [15]. QSYQ could regulate the expressions
of proteins associated with energy metabolism in ischemic
myocardium of rats [16].
This study aims to test the “Jun-Chen-Zuo-Shi” rule of
QSYQ in treating AMI by a network pharmacology ap-
proach. We developed a network pharmacology based
approach, NRI- organism disturbed network (ODN), to
investigate the compatibility law of CM formula from
both molecule network and pathway level. Firstly, ODN
was constructed with disease-related genes, gene expressionFigure 1 Study workflow. Three kinds of information were collected, incl
construct the AMI-ODN. The genes in AMI-ODN network were further an
status of drug on the AMI-ODN. The efficacy of QSYQ and its component her
overall recovery ability. On the other side, pathway enrichment analysis was
demonstrated the synergistic effect of QSYQ on treating AMI from moledata and protein-protein interaction (PPI) information to
determine the disease systematic influences on the biological
network. By combining topology analysis on the ODN and
recovery regulation analysis, the gene nodes were weighted
by both their topology attributes and recovery ability in
regulation of gene expression.
Methods
Study workflow
A study workflow was shown in Figure 1. The AMI-ODN
was constructed with AMI-related genes and related PPIs.
The network was then annotated with gene expression
data. Genes with recovery regulation trend would be eval-
uated and highlighted (as blue nodes) in the network.
NRI-ODN score was used to evaluate the drug efficacy of
QSYQ and its component herbs. Additionally, efficient re-
covery genes (ERGs) from AMI-ODN by QSYQ and its
component herbs were calculated, and pathway enrich-
ment analysis with KEGG pathway database was applied
to these genes to investigate enriched biological pathways.uding AMI-related genes, PPIs information and microarray data to
notated with recovery regulation of drugs, to visually reveal the recover
bs were then measured by NRI-ODN, a network based index to evaluating
applied on ERGs of QSYQ and its component herbs. As a result, we
cule network and pathway level.
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Male Sprague-Dawley rats (220-250 g) were purchased
from Zhejiang Experimental Animal Center (China). The
animal experiments were performed according to guide-
lines of the Animal Ethics Review Committees of Zhejiang
University. AMI Rat model was produced through the oc-
clusion of the left anterior descending coronary artery
according to Yamaguchi et al. [17,18]. The detailed
procedure of rat experiment was described by Hong
et al. [16]. Sham-operated rats with no ligation suture
served as control group (Control). Surviving animals
were arbitrarily divided into acute myocardial ischemia
group (AMI) and QSYQ-treated group, Astragalus -treated
group, Salvia-treated group, Notoginseng-treated group
and Dalbergia-treated group. Each group included at least
8 rats for calculating a weight ratio of infarct heart tissue
calculation and 3 rats for microarray experiments. Instead
of using dropping pills, QSYQ extracts, composed by ex-
tracts of Astragalus, Salvia, Notoginseng and Dalbergia,
was used in this study to investigate the “Jun-Chen-Zuo-
Shi” rule. The dosage of QSYQ and each component
herb extracts used in this work was listed as follows:
Astragalus extracts (105.7 mg/kg/day), Salvia extracts
(84.9 mg/kg/day), Notoginseng extracts (9.4 mg/kg/day),
and volatile oil extracted from Dalbergia (4.7 μL/kg/day).
Rats in Control and AMI groups were administered with
saline. After treatment for 7 days, rats were sacrificed. The
border between infarct and non-infarct left ventricle area
in rat heart were harvested to extract mRNA.
RNA extraction and microarray experiments
Total RNA was extracted and purified by TRIZol Re-
agent (Invitrogen, USA) and RNeasy Mini kit (QIAGEN,
Germany). An Agilent 2100 Bioanalyzer and electrophoresis
in 2% (v/v) agarose gels were used for quality assessment of
RNA. Only RNA samples with RNA integrity numbers
(RINs) over 7.0 and 28SrRNA/18S rRNA greater than 0.7
were used for further microarray experiments. Whole gen-
ome microarray analysis was performed using Affymetrix
rat Genome 230 2.0 chips (Affymetrix, USA) in accordance
with the manufacturer’s protocol. Spike-in control tran-
scripts were monitored to verify hybridization integrity.
ODN model construction
AMI related gene information is collected from gene
knowledgebase such as CHD@ZJU [19] and RGD [20],
and the PPI relationships of these genes are collected
from public PPI databases HPRD [21] and BioGRID
[22], to construct the AMI-ODN. Then, expression value
of AMI-related genes is obtained from microarray exper-
iments. Expression value is firstly used as a filter, only
genes with considerable intensity and significant expres-
sion changes (measured by fold change, equation 1) will
be considered in the final AMI-ODN. If a gene hadmultiple corresponding probes, the largest (in absolute)
fold change among all probes was used.
FC ¼ LogEdisease−LogEcontrol ð1Þ
where FC indicates the Fold Change, LogEdisease indicates
the Log2 expression value of disease group, and LogEcontrol
indicates the Log2 expression value of control group.
The details of AMI-ODN construction were as follows.
(1) In the step of gene collection, two public databases,
CHD@ZJU (Version 1.0; includes 660 coronary heart
disease related genes) [19] and Rat Genome Database
(RGD; totally 366 genes are reported to be related with
myocardial ischemia) [20] cardiovascular portal, were
used. By integrating these two database, 820 unique
genes are found. (2) In the step of gene filtering, AMI
group averaged Log2 normalized intensity (aver_Log2 > 5)
and absolute value of fold change between AMI and con-
trol group (abs_FC > 0.2) were used as thresholds to iden-
tify considerably and significantly altered expression of
AMI-related genes. (3) In the step of PPI information col-
lection, PPIs were collected from two PPI database, HPRD
(included 41327 human PPIs with supporting literature
evidences) [21] and BioGRID (contained 209838 PPIs)
[22]. Only the PPIs that involve AMI-related genes as both
source and target genes were used. (4) Finally, the quali-
fied AMI related genes and PPIs were used to construct a
AMI-related PPI network by Cytoscape [23], and the
AMI-ODN was defined as the biggest sub-network (the
giant component).
NRI-ODN and efficiency of recovery regulation
Network recovery index (NRI) was previously proposed
by our group to determine the drug efficacy of CM [11]
and was measured according to equation 2a. The recovery
regulation and regulation level are measured according to
equation 2b and equation 2c. In equation 2c, LogE repre-
sents Log2 normalized intensity of experimental group,
and equation 2b represents the ratio of genes with ability
to recover the AMI network to normal states. NRI indi-
cates the network recovery index, RR indicates recovery
regulation, and RL indicates the regulation level.
NRI ¼ RRall þ RRup þ RRdown ð2aÞ






The nodes with positive regulation level contribute
equally to the final NRI score. The topology and efficiency
of recovery regulation are not considered in this study.
However, the topology of node described the biological
importance of the gene node to the whole ODN, such as
Wu et al. Chinese Medicine 2014, 9:24 Page 4 of 9
http://www.cmjournal.org/content/9/1/24the nodes with high degrees in a biological network are
probably more important genes in the biological system.
On the other hand, the efficiency of recovery regulation
(EoR) also could quantitatively indicate the drug ability to
recover altered gene expression.
RR was optimized and replaced by RR-ODN to meas-
ure the nodes recovery ability by considering their top-
ology and EoR, as equation 3a. The topology weight was
the degree centrality of node, which represented the
number of directly connected neighboring nodes. The
nodes with EoR < 0 (regulation level >2 or <0) would not
be used to calculate RR-ODN calculation. Finally the
NRI-ODN was measured according to equation 3b.
RRODN ¼
X
Wtopo  EoRpositive ð3aÞ
NRIODN ¼ RRODNall þ RRODNup þ RRODNdown
ð3bÞ
where W indicates the topology weight parameter,
RRODN indicates the new recovery regulation index in
NRI-ODN.
EoR was the efficiency of a drug to recover disturbed
gene as defined in equation 4. 50% EoR would mean that
the drug could recover the gene dysregulation by half
(7.5) or 50% over-regulated the gene expression (12.5);
100% EoR would mean that the drug could fully recover
the gene expression from disease to control state (10). In
this study, EoR ≥ 50% was used as a threshold of identify
efficient recovery regulated genes (ERGs).











Sham MI Astragalus Sa
: significant compared to MI group (P<0.05)
: strongly significant compared to MI group (P<0.01)
Figure 2 Statistics of the weight ratio of infarcted heart tissue in rat e
more significantly than its component herbs, i.e., Astragalus, Salvia, NotoginPathway enrichment analysis
Pathway enrichment analysis with KEGG pathway data-
base [24] was applied on ERGs of QSYQ and its com-
ponent herbs, in which the ERGs was defined as the
genes with EoR > 50%. By using ArrayTrack [24], an
enriched pathway represented those pathways which
had a Fisher P value <0.05. Only the pathways of cellu-
lar processes and environmental information processes
were considered.
Results
The weight ratio of infarcted heart tissue
Therapeutic effects of QSYQ treatment and each indi-
vidual component treatment were evaluated by the
weight ratio of infarcted heart tissue. As shown in
Figure 2, the AMI injury was quantitatively evaluated
for each group by the weight ratios between infarcted
zone and the whole tissue. The QSYQ showed efficacy
on treating AMI by significantly reducing the weight
ratio of infarcted heart tissue (P = 0.002), with a lower
P value than any of its component. Among four com-
ponent herbs, Astragalus and Salvia also showed significant
effect on treating AMI (P = 0.02 and 0.01, respectively),
but Notoginseng and Dalbergia showed insignificant
effects (P > 0.1).
AMI-ODN construction
By integrating gene information from CHD@ZJU and
RGD, 820 AMI related genes were found. Fold change >0.2
and average Log2 normalized intensity >5 were then used
to find significant expressed and changed genes in the
microarray experiments, and PPIs among these genes were
found from HPRD and BioGRID databases. As a result,lvia Notoginseng Dalbergia QSYQ
xperiments. QSYQ reduced the weight ratio of infarcted heart tissue
seng and Dalbergia, did.
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used to construct the AMI-related PPI network. The big-
gest sub-network contained 281 genes and 616 PPI rela-
tionships, which were then defined as the AMI-ODN
(Figure 3a).
We calculated the regulation level of QSYQ on the
AMI-ODN, and annotated the node color to show the
recovery status (Figure 3b). The genes with positive regu-
lation, indicating recovered regulation, were colored in
blue. The regulation levels of component herbs were also
visualized as shown in Figure 3c. Apparently, QSYQ could
affect most of the nodes in the ODN which was disturbed
in the disease state.
Evaluating efficacy and synergistic effect of QSYQ
The NRI-ODN was then measured to quantitatively evalu-
ate the drug efficacy of QSYQ and its component herbs
(Table 1). For instance, the RR-ODN of QSYQ for all net-
work, significantly down-regulated nodes and significantly
up-regulated nodes were 513.03, 78.45 and 273.00,
respectively. The score of NRI-ODN of QSYQ was
864.48, which showed better recovery performance com-
pare to its components. Among the four component
herbs, Salvia showed the highest NRI-ODN (734.31)
which was slightly higher than that of Astragalus (680.27),
whereas Notoginseng (545.76) and Dalbergia (584.88)
showed relatively lower NRI-ODN scores. According to
the “Jun-Chen-Zuo-Shi” rule, Astragalus (Sovereign) and
Salvia (Minister) were expected to recover disturbed net-
work better than Notoginseng (Assistant) and Dalbergia
(Courier) did, which was accordance to the NRI-ODN
result.
A permutation test was performed to check whether
QSYQ and its component herbs recovered ODN net-
work more significantly than any random permutation
in ODN with a normal distribution. The NRI-ODN of each
permutation was calculated and repeated 10000 times. As a
result, the average value of permutated NRI-ODN was
471.96, and the standard deviation was 55.64 in 10000 rep-
etitions. The P value of NRI-ODN of QSYQ and its com-
ponent herbs was calculated from the permutation test
(Table 1). Astragalus and Salvia showed a highly signifi-
cant recovery from a disturbed network (P < 0.01), and
Dalbergia showed a significant recovery (P < 0.05), while
the recovery of Notoginseng on ODN was not statistically
significant (P = 0.18).
The effect of fold change threshold on NRI-ODN
calculation
In NRI-ODN calculation, the up-regulated and down-
regulated genes were identified by fold changes. The
effect of fold change thresholds on the RR-ODN calcu-
lation was investigated. In Figure 4, the x-axis repre-
sented the threshold of fold change. For instance, x = 0.1is the threshold to identify the up-regulated genes with
fold change >0.1 and the down-regulated genes with fold
changes < -0.1. In particular, x = 0 meant the same as RR-
ODNall. The y-axis was the total significantly regulated
RR-ODN score which contributed by both up-regulated
and down-regulated genes. The green line represented the
RR-ODN of QSYQ, and the orange, red, blue and pur-
ple lines represented the RR-ODN of Astragalus, Salvia,
Notoginseng and Dalbergia, respectively. The overall RR-
ODN of QSYQ and its component herbs were consistent
when fold change threshold <1. The performance of
QSYQ was more effective than any individual compo-
nent herb. The performances of Astragalus and Salvia
were equivalent and significantly better than perfor-
mances of Notoginseng and Dalbergia. When fold change
threshold was set >1, there were fewer genes (only 34
genes remained with fold change >1) which RR-ODN re-
sult was seriously influenced by any single node’s perform-
ance. Therefore, fold change =0.5 was used as the
threshold to identify significantly regulated genes. In this
study, 169 significantly regulated genes were found.
Pathway enrichment analysis
ERGs were defined by EoR > 50%. There were 131, 90,
111, 76 and 89 ERGs in the ODN for QSYQ, Astragalus,
Salvia, Notoginseng and Dalbergia, respectively. Pathway
enrichment analysis was conducted on the effective regu-
lation recovery genes of QSYQ and its component herbs.
The number of significant enriched pathway (Fisher’s
p-value <0.05) of QSYQ was significantly more than its
component herbs, Salvia, Notoginseng and Dalbergia
(Table 2). However, Astragalus had more enriched path-
ways than QSYQ did.
The numbers of overlapping pathways between QSYQ
and a component herb including Astragalus, Salvia, Noto-
ginseng, and Dalbergia were 10, 10, 8 and 5, respectively.
The result indicated that Salvia and Notoginseng acted on
p53 pathways whereas Astragalus and Dalbergia did not.
It suggested that the effect of QSYQ on p53 signaling
pathway was attributed to Salvia and Notoginseng. De-
tailed pathway information of QSYQ and its component
herbs were provided in Table 3.
Out of 16 pathways, three of them, as complement
and coagulation cascades, cytokine-cytokine receptor
interaction and MAPK signaling pathway, were enriched
in QSYQ and all its four component herbs. On the other
hand, two pathways, i.e., cell adhesion molecules and
regulation of actin cytoskeleton, were specially enriched
by QSYQ, which might imply novel function of compo-
nent combination.
As shown in Table 3, all enriched pathways of Noto-
ginseng and Dalbergia were at least enriched in either
Astragalus or Salvia, which suggested that Notoginseng
and Dalbergia might play roles as Zuo (assistants) that
Figure 3 Recovery regulation of QSYQ and its components on AMI-ODN. (a) The AMI-ODN contained 281 nodes and 616 edges. Node was
annotated with its expression fold changes between AMI and control group, red indicated up-regulation and green indicated down-regulation.
(b) Recovery regulation of QSYQ on AMI-ODN. Nodes in AMI-ODN with recovery regulation were colored in blue, indicating that QSYQ could
recover this gene node from disease to control state. Grey nodes represented a negative regulation level. (c) Recovery regulation of Astragalus,
Salvia, Notoginseng and Dalbergia on AMI-ODN.
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Table 1 NRI-ODN results of QSYQ and its component herbs
QSYQ Astragalus Salvia Notoginseng Dalbergia
RR-ODN
(All)
513.03 399.40 432.18 318.14 362.31
RR-ODN
(Down)
78.45 74.59 80.96 48.50 76.77
RR-ODN
(Up)
273.00 206.28 221.17 179.12 145.81
NRI-ODN 864.48 680.27 734.31 545.76 584.88
P value 1.84E-12** 1.82E-04** 2.45E-06** 0.185 0.042*
**Extremely significant (<0.01).
*significant (<0.05).
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but to enforce regulating effects of Astragalus and Salvia
enriched pathways.
In Table 3, vascular smooth muscle contraction, apoptosis,
PPAR signaling pathway and Toll-like receptor signaling
pathway are enriched by Astragalus but not Salvia. Among
them, vascular smooth muscle contraction reflected the
roles of vascular smooth muscle cell (VSMC) to regulate the
blood flow and pressure [25]. PPAR signaling pathway was
highly correlated with lipids metabolism and adipocyte dif-
ferentiation. These two enriched pathways might indicate
the Astragalus would play roles on energy metabolism
to relieve the blood flow dysregulation caused by acute
myocardial ischemia. Apoptosis and Toll-like receptor
signaling pathway were correlated with cell death andFigure 4 The RR-ODN with top N genes (ranged from 1 to 281) sorted
and y-axis represents RR-ODN of QSYQ and its component herbs. QSYQ sh
four component herbs, Astragalus and Salvia showed higher RR-ODN than Nimmune system [26,27], which implied potential roles
of Astragalus on these biological functions. Astragalus
regulated BCL-2 protein family (such as BCL-2 and
BAX), which was critical in apoptosis and correlated
with p53 and TGF-beta signaling pathway [28]. Astrag-
alus also reduced expression of BAX in heart failure
rats and increase Bcl-2 expression by Astragaloside IV,
a main component in Astragalus [29,30].
On the other side, endocytosis, TGF-beta signaling
pathway, p53 signaling pathway and ECM-receptor
interaction were enriched by Salvia but not Astragalus.
Activation of TGF-beta signaling pathway was found
in the infarcted myocardium with potential effects on
repression of inflammatory genes and mediating reso-
lution of the inflammatory infiltrate TGF-beta also me-
diates events in the pathogenesis of hypertrophic and
dilative ventricular remodeling [31]. P53 signaling pathway
was induced by stress signals, such as DNA damage, oxi-
dative stress, and was correlated with apoptosis and cell
cycle arrest [32]. The enrichment of TGF-beta signaling
pathway and p53 signaling pathway indicated the Salvia
might play important roles in apoptosis, which was also
regulated by Astragalus.
Furthermore, Astragalus, Salvia and Notoginseng could
regulate Chemokine signaling pathway together, which
was highly correlated with inflammation processes
[33]. In all, the QSYQ might gain enhanced drug effect by
regulating apoptosis and inflammation related pathways
together.by absolute fold changes. The x-axis represents number of genes
owed the better RR-ODN than its individual component herbs. Among
otoginseng and Dalbergia, in accordance with their primary roles in QSYQ.
Table 2 Number of enriched pathways of QSYQ and its
component herbs
QSYQ Astragalus Salvia Notoginseng Dalbergia
Number of
ERGs
131 90 111 76 89
Cellular
processes




5 4 6 3 4
Total biological
pathways
16 18 13 13 12
Overlapped
pathways
– 10 10 8 5
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In this study, we integrated AMI-related gene and its ex-
pression data, with PPI information to construct AMI-
ODN model, and further applied the network model to
reveal the compatibility law of QSYQ on treating AMI.
In particular, the network recover ability of QSYQ and
its component herbs were quantitatively measured by
NRI-ODN to demonstrate that the synergistic efficacy of
QSYQ on treating AMI. Among four component herbs,
Astragalus and Salvia showed stronger recovery ability
than Notoginseng and Dalbergia, which was also con-
formed to the “Jun-Chen-Zuo-Shi” rule of QSYQ.
The primary roles of Astragalus and Salvia in QSYQ
were further validated at pathway level. By pathwayTable 3 Enriched pathway results of QSYQ and its componen
Pathway Name KEGG ID QSYQ
Complement and coagulation cascades hsa04610 1
Cytokine-cytokine receptor interaction hsa04060 1
MAPK signaling pathway hsa04010 1
Chemokine signaling pathway hsa04062 1
Focal adhesion hsa04510 1
Adipocytokine signaling pathway hsa04920 1
Endocytosis hsa04144 1
TGF-beta signaling pathway hsa04350 1
p53 signaling pathway hsa04115 1
ECM-receptor interaction hsa04512 1
Vascular smooth muscle contraction hsa04270 1
Apoptosis hsa04210 1
PPAR signaling pathway hsa03320 1
Toll-like receptor signaling pathway hsa04620 1
Cell adhesion molecules hsa04514 1
Regulation of actin cytoskeleton hsa04810 1enrichment analysis, Astragalus and Salvia could regu-
late more pathways and play special roles on unique
pathways, such as Astragalus could regulate energy
metabolism to relieve the blood flow caused by myo-
cardial ischemia. The combination of Astragalus and
Salvia could also enhance the regulating ability of import-
ant biological processes, such as apoptosis and inflamma-
tion system.
The successful application of network-based approaches
on QSYQ was more sensitive than traditional, phenotype-
based evaluating method, such as the weight of infarcted
zones. More importantly, the synergistic effect and contri-
bution of drug efficacy could now be evaluated from a
molecule network and pathway level, which was further
related to its underlying “multi-target, multi-processes”
mechanisms.
ODN modeling and evaluation with NRI-ODN score
were suitable for studying high-throughput data and com-
plex diseases which involved multiple genes. It might have
limited performance for orphan diseases. ODN modeling
was independent of chemical structures, and suitable for
discovering the similar and distinct effects between CM
and chemical drugs.Conclusion
AMI-ODN model and NRI-ODN identified the pos-
sible roles of “Jun-Chen-Zuo-Shi” component herbs of
QSYQ in treating AMI at molecular network and path-
way level.t herbs
Salvia Astragalus Notoginseng Dalbergia
1 1 1 1
1 1 1 1
1 1 1 1
1 1 1 0
1 1 0 1
1 1 0 0
1 0 1 1
1 0 1 0
1 0 1 0
1 0 0 0
0 1 1 0
0 1 0 0
0 1 0 0
0 1 0 0
0 0 0 0
0 0 0 0
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